The aryl hydrocarbon receptor (AHR) is a basic helix-loop-helix/Per-ARNT-Sim domain transcription factor, which is activated by various xenobiotic ligands. AHR is known to be abundant in liver tissue and to be associated with hepatic steatosis. However, it has not yet been elucidated how the activation of AHR promotes hepatic steatosis. The aim of this study is to clarify the role of AHR in hepatic steatosis. The intraperitoneal injection of 3-methylcholanthrene (3MC), a potent AHR ligand, into C57BL/6J mice significantly increased the levels of triglycerides and 6 long-chain monounsaturated fatty acids in the livers of mice, resulting in hepatic microvesicular steatosis. 3MC significantly enhanced the expression level of fatty acid translocase (FAT), a factor regulating the uptake of long-chain fatty acids into hepatocytes, in the liver. In an in vitro experiment using human hepatoma HepG2 cells, 3MC increased the expression level of FAT, and the downregulation of AHR by AHR siRNA led to the suppression of 3MC-induced FAT expression. In addition, the mRNA level of peroxisome proliferator-activated receptor (PPAR) α, an upstream factor of FAT, was increased in the livers of 3MC-treated mice. Taking together, AHR activation induces hepatic microvesicular steatosis by increasing the expression level of FAT.
Introduction
The aryl hydrocarbon receptor (AHR) is a ligand-dependent basic helix-loop-helix/Per-ARNT-Sim domain transcription factor [1] . AHR is activated by various exogenous agonists, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), polychlorinated biphenyl (PCB), benzo[a]pyrene (BaP), and 3-methylcholanthrene (3MC) [2, 3] . In addition, some endogenous ligands, for example, indigo and indirubin, are known to bind to AHR [4] . These ligands bind to cytosolic AHR, and then the activated AHR translocates into the nucleus, heterodimerizes with the AHR nuclear translocator (ARNT) and binds to specific enhancer sequences adjacent to target promoters termed "dioxin responsive elements" (DRE) [5] . Its activation leads to various toxic responses including tumor-promotion, teratogenicity, immunotoxicity, and lethality [6] . In previous studies, it was reported that AHR is abundant in liver tissue [7] , which is one of the major target organs for AHR-related toxicity, such as fat accumulation, inflammation, and fibrosis, in laboratory animals [8, 9] . Boverhof et al. demonstrated that C57BL/6 mice gavaged with TCDD exhibited lipid accumulation in their liver tissue 7 days after exposure [9] . Korenaga et al. also revealed that rhesus monkeys that were subcutaneously administered TCDD for 4 years exhibited intrahepatic fatty changes [10] . However, the molecular mechanisms underlying fat accumulation induced by AHR activation have not been elucidated.
A variety of lipid metabolic pathways occur in the liver. The accumulation of lipids in the liver is also induced through several signaling pathways, and excessive lipid accumulation may lead to fatty liver. The liver is the major tissue of de novo lipogenesis, which is regulated by fatty acid synthase (FAS), and the upregulation of FAS causes increased triglyceride synthesis [11] . The enhanced uptake of fatty acids also leads to the accumulation of lipids in the liver. Free fatty acids enter cells via fatty acid translocase (FAT) and then bind to liver fatty acid binding protein (L-FABP), before transporting free fatty acids to mitochondria, where they will undergo metabolic conversion or be used to synthesize triglycerides [12, 13] . In addition, the accumulation of lipids in the liver is induced through the downregulation of lipid catabolism, for example, via β-oxidation. Carnitine 5 palmitoyltransferase (CPT) 1 controls the transport of long-chain acyl-CoA into mitochondria, in which β-oxidation occurs, and reduced CPT1 activity leads to lipid accumulation accompanied by the downregulation of β-oxidation [14] . Triglycerides bind to apolipoprotein B to construct mature lipoprotein particles for secretion, and microsomal triglyceride transfer protein (MTP) plays a critical role in the assembly and secretion of very low density lipoproteins (VLDL) [15] . Therefore, decreased hepatic export of triglycerides as VLDL leads to lipid accumulation in the liver.
Nuclear factors are also important for the regulation of lipid metabolism. Fatty acid metabolism is transcriptionally regulated by two main systems; i.e., the liver X receptor (LXR) and peroxisome proliferator-activated receptor (PPAR)-related pathways. LXR activates the expression of sterol regulatory element binding proteins (SREBP)-1c, a dominant lipogenic gene regulator. On the other hand, peroxisomal, microsomal, and mitochondrial fatty acid metabolizing enzymes in the liver are transcriptionally regulated by PPARα [16] . However, the relationship between AHR activation and fatty acid metabolism has not been elucidated. Therefore, the aim of this study is to examine the role of AHR in hepatic steatosis. 
Materials and methods

Animal treatment
All animal treatments in this study were approved by the Institutional Animal Care and Use Committee and carried out according to the Kobe University Animal Experimentation Regulations.
Male C57BL/6J mice (15 weeks old, CLEA Japan, Tokyo, Japan) were housed in a temperature controlled (23-25°C) room at 60±5% humidity under a 12-h light-dark cycle and acclimatized for 7 days with a commercial chow and distilled water. The mice fed the standard chow were randomly divided into 2 groups of 5 mice each, and one group received a single intraperitoneal injection of 3MC (Sigma, Tokyo, Japan) at 100 mg/kg body weight (BW). The other group was given 0.25 mL of corn oil (Nacalai tesque, Kyoto, Japan) as a vehicle control. After 8 hours, 5 mice from each group were killed, and their livers were removed. Blood was collected via cardiac puncture, and the serum was separated by centrifugation at 1,000 × g for 10 min at 4 o C.
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Dyer [17] . Briefly, the liver tissue was homogenized with 9 volumes of 1.15% (w/v) KCl, aliquots (0.5 ml) of homogenate were extracted with 5 mL of chloroform-methanol (2:1) solution 3 times, and the chloroform layer was then collected by centrifugation at 1,000 × g for 10 min. To remove water-soluble substances, a 1/5 volume of 0.5% (w/v) NaCl was layered onto the chloroform extract, vortexed, and centrifuged at 1,000 × g for 10 min. The resultant chloroform layer was evaporated just before use, dissolved in methanol, and its lipid levels were measured. Triglyceride levels were measured using a commercial kit (Wako Pure Chemical Industries Ltd.) according to the manufacturer's instructions.
Measurement of fatty acids by gas chromatography-mass spectrometry (GC-MS)
Commercial kits were used for the methylation and purification of fatty acids in the liver (Nacalai tesque). The resultant solution was evaporated under a stream of N 2 gas, and methyl esters of fatty acids were measured by GC-MS after being dissolved in n-hexane. All GC-MS analyses were performed by GCMS-2010plus (Shimadzu, Kyoto, Japan). In the gas chromatographic system, a 
Isolation of total RNA and the quantitative real-time polymerase chain reaction (PCR)
Total RNA was isolated from the cultured cells or liver tissue with TRIzol Reagent (Invitrogen, Tokyo, Japan), according to the manufacturer's instructions. cDNA was prepared using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Tokyo, Japan), and then quantitative real-time PCR was performed using the 7500 Real Time PCR System and Power SYBR Green Reagent (Applied Biosystems). The specific primers were synthesized by Hokkaido System 8 Science (Sapporo, Japan), and the sequences of the primers are listed in Table 1 .
Western blot analysis.
To prepare cell or tissue lysate, they were homogenized with 8 TBST under the same conditions, the membrane was incubated with the appropriate secondary antibody conjugated with horseradish peroxidase for 1 h at room temperature. The specific immune complexes were detected with Chemi-Lumi One L (Nacalai tesque), and the density of specific bands was determined with LAS-4000 mini (FUJIFILM, Tokyo, Japan).
Cell culture and RNA interference analysis.
Human hepatoma HepG2 cells were grown in Dulbecco's modified Eagle's medium (DMEM) (Nacalai tesque) supplemented with 10% fetal bovine serum (FBS), 100U/ml penicillin, and 100μg/ml streptomycin under a humidified 95% air/5% CO 2 Western blotting, respectively, as described above.
Statistical analysis.
All data are expressed as the mean ± standard error (SE) of at least three independent determinations for each experiment. Statistical significance was analyzed using the Student's t-test, and a level of probability of 0.05 was used as the criterion for significance.
Results
Effects of 3MC on lipid levels in plasma and the liver
To investigate the involvement of AHR in hepatic steatosis, 3MC, an agonist of AHR, was used, and C57BL/6J mice were intraperitoneally given 3MC at 100 mg/kg BW. In liver histology assessed by
Oil Red O staining, microvesicular fat accumulation was observed around the central vein in the 3MC-treated mice (Fig. 1A) . Next, triglycerides were extracted from the liver, and the quantitative measurement of triglycerides was performed. The triglyceride level in the livers of the 3MC-treated mice was 1.5-fold higher than that in the corresponding control mice (p<0.05, Fig. 1B) . No significant effects of 3MC on the serum levels of ALT, total bilirubin, total cholesterol, triglyceride, free fatty acid, and glucose were confirmed ( Table 2) .
Fatty acid constituents in the liver
To examine whether the fatty acid levels in the liver are increased by AHR activation, the concentrations of 51 fatty acids in the liver were measured by GC-MS. In our experimental conditions, 32 fatty acids were detected. In the 3MC-treated mice, the levels of 6 monounsaturated fatty acids (MUFA); i.e., C14:1, C16:1, C18:1, trans-C18:1, C20:1, and C22:1, and 1 saturated fatty acid (SFA); i.e., C16:0, were significantly increased in comparison to those of the corresponding control mice, whereas the levels of 1 SFA; i.e., C24:0, were significantly decreased. No significant effects of 3MC on other SFA or polyunsaturated fatty acids (PUFA) were confirmed (Table 3) .
Changes in the expression levels of hepatic CYP1A1 and fatty acid-related factors
To elucidate the mechanisms by which 3MC induces hepatic steatosis, the effects of 3MC on the hepatic factors involved in fatty acid uptake, synthesis, oxidation, and secretion were examined by real-time PCR. 3MC significantly upregulated the expression of cytochrome P450 1A1 (CYP1A1) and FAT mRNA in the liver by approximately 2.0×10mRNA in the livers of the mice that received 3MC tended to be decreased compared with that in the control mice (Fig. 2F ). In addition, the protein level of FAT was significantly increased by approximately 1.9-fold (Fig. 3 ). These data demonstrate that hepatic steatosis induced by AHR activation is accompanied by upregulated FAT expression.
Changes in the expression levels of hepatic AHR, PPARα, RXRα, LXRα, and SREBP1
Next, the changes in the expression levels of hepatic AHR and the factors related to lipid metabolism were investigated by real-time PCR. In the 3MC-treated mice, significant increases in the mRNA levels of AHR and PPARα were observed (Fig. 4A, B) , while the levels of retinoid X receptor (RXR) α and LXRα mRNA remained unchanged (Fig. 4C, D) . SREBP1 mRNA expression was downregulated without attaining statistical significance (Fig. 4E) .
Suppression of FAT expression thorough the downregulation of AHR expression in HepG2 cells
It was investigated whether the 3MC-induced upregulation of FAT depends on AHR. In this study, RNA interference using AHR siRNA was performed. In AHR siRNA-transfected HepG2 cells, the downregulation of AHR mRNA and protein expression was observed, although complete knockdown of its expression was not achieved (Fig. 5A, 6 ). Downregulation of AHR also led to the suppression of 3MC-enhanced expression of CYP1A1 mRNA (Fig. 5B) . In control siRNA-transfected HepG2 cells, 3MC increased the expression levels of FAT mRNA and protein, but no induction of FAT mRNA or protein by 3MC was observed in the AHR siRNA-transfected
Discussion
This study was designed to examine the role of AHR in intrahepatic fat accumulation. We used 3MC
as an agonist of AHR. 3MC is a synthetic compound and a highly potent member of the polycyclic aromatic hydrocarbon family of chemicals [3] , which are found in cigarette smoke [18] . In a previous study, it was reported that TCDD induced hepatic steatosis as a chronic toxicity [9, 10] .
However, to the best of our knowledge, this is the first study to demonstrate that an AHR agonist induces hepatic microvesicular steatosis as an acute toxicity (Fig. 1A, 1B) . In the 3MC-treated mice, no liver damage was observed in examinations of their histology and serum ALT levels (Fig. 1A , Table 2 ). The steatosis was improved 24 hr after 3MC injection (data not shown). This may have been because 3MC is metabolized and eliminated quickly from the liver. In fact, Moorthy demonstrated that only 0.94% of the administered dose remained in the liver 1 day after the intraperitoneal injection of 3MC [19] . These results strengthen the assertion that 3MC induced hepatic microvesicular steatosis as an acute toxicity in the current study.
The most interesting finding of the current study was the upregulation of FAT expression induced by AHR activation in vivo. In addition, in an in vitro experiment, it was confirmed that the upregulation of FAT expression by 3MC is dependent on AHR (Fig. 5C, 6 ). Although one of the causes of hepatic steatosis is the upregulation of FAS expression, FAS mRNA expression tended to be downregulated in the 3MC-treated mice (Fig. 2F ). DNA microarray analysis by Sato et al. also exhibited decreased FAS mRNA expression in the livers of TCDD-treated mice [20] . To the best of our knowledge, our results are the first to confirm the increased FAT expression in the livers of 3MC-injected mice (Fig.   2B, 3 ) and the involvement of AHR in 3MC-evoked induction of FAT expression (Fig. 5C, 6 ).
Probably, 3MC-induced intrahepatic microvesicular steatosis results from increased levels of triglycerides, palmitic acid (C16:0), and 6 long-chain MUFA in the liver (Fig. 1B, Table 3 ). On the basis of a previous report [21] , 3MC-induced steatosis is considered to be caused by the upregulation of FAT expression in the liver, leading to an enhanced rate of long-chain fatty acid uptake and increased triglyceride synthesis, because de novo lipogenesis in the livers of 3MC-treated mice was 13 not upregulated, and furthermore, β-oxidation and VLDL export were not downregulated (Fig. 2C,   2D , 2E, 2F). This is consistent with previous studies as outlined below. In a mouse model fed a high fat diet, increased expression of hepatic FAT protein was sufficient to exacerbate hepatic triglyceride storage and to increase the MUFA content of the liver [12, 22] . It was also reported that the expression level of FAT mRNA was upregulated in the livers of patients diagnosed with nonalcoholic fatty liver disease (NAFLD), and moreover palmitic acid (C16:0) and MUFA were the predominant fatty acids in the livers of these patients [23, 24] . Metabolic disorders, such as hyperglycemia and dyslipidemia, are observed in a mouse model of NAFLD and are well-known risk factors for NAFLD [25, 26] . However, no 3MC-induced significant alterations of the serum levels of total cholesterol, triglyceride, free fatty acid, or glucose were confirmed ( Table 2 ). This may have been because 3MC caused acute toxicity in our experimental conditions. If mice are continuously administered 3MC, it is possible that they will exhibit metabolic disorders. Remillard et al. showed that TCDD causes loss of body weight and a decrease in adipose tissue weight, which is also known as wasting syndrome, and this syndrome leads to increased serum lipid levels and disordered distribution of lipids, resulting in diabetes-like symptoms [27] . TCDD is difficult to metabolize and easily accumulates in the body. Therefore, AHR activation as an acute toxicity induces hepatic microvesicular steatosis, while AHR activation as a chronic toxicity causes metabolic disorders.
Our data also demonstrated that the mRNA expression levels of PPARα and FAT were significantly increased (Fig. 2B, 4B ). It was reported that FAT mRNA expression is induced by PPARα in the liver [28] , suggesting that the induction of FAT expression by AHR activation is regulated through PPARα (Fig. 7) . Recently, it was revealed that PPARα activation by its agonists transcriptionally induced AHR and CYP1A1 expression through PPRE sites located within its promoter [29, 30] .
Although it is unknown whether the functions of PPARα are upregulated by AHR activation, the close interaction between AHR and PPARα may be mediated in the liver. Further experiments are required to elucidate the molecular mechanisms behind our findings.
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In conclusion, our study highlights the importance of FAT in hepatic microvesicular steatosis caused by AHR activation. The upregulation of FAT expression results in an increased rate of long-chain MUFA uptake into hepatocytes. These findings are similar to the symptoms of patients with NAFLD.
There are no established effective therapeutic modalities for NAFLD progression, and such modalities are urgently required. This study may be helpful for researchers aiming to find a novel target that can be used to prevent NAFLD progression. However, AHR activation does not affect fatty acid transport, β-oxidation, or VLDL synthesis. The current study proposes the existence of an interaction between AHR and PPARα. The sera were collected from the mice 8 hours after the injection of 3MC or corn oil as a vehicle control. Values are the mean ± SE (n=5/group); N.S., not significant. ALT, alanine aminotransferase.
